Eupraxia Pharmaceuticals (NASDAQ:EPRX) Price Target Raised to $19.00

Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its price target upped by Cantor Fitzgerald from $11.00 to $19.00 in a research report report published on Thursday, MarketBeat.com reports. They currently have an overweight rating on the stock.

Several other equities research analysts have also recently weighed in on the stock. Leede Financial upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, October 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, October 8th. Lifesci Capital upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 11th. Wall Street Zen raised shares of Eupraxia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Eupraxia Pharmaceuticals in a research note on Friday, January 9th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Eupraxia Pharmaceuticals presently has an average rating of “Buy” and an average target price of $14.33.

Eupraxia Pharmaceuticals Trading Down 0.2%

NASDAQ:EPRX opened at $8.75 on Thursday. The business’s 50-day moving average is $6.86 and its 200 day moving average is $6.00. Eupraxia Pharmaceuticals has a 12 month low of $2.68 and a 12 month high of $8.89. The company has a market capitalization of $314.65 million, a P/E ratio of -10.06 and a beta of 1.21.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. On average, research analysts forecast that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current year.

Institutional Trading of Eupraxia Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Royal Bank of Canada grew its stake in Eupraxia Pharmaceuticals by 21.1% in the first quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock worth $1,125,000 after purchasing an additional 59,683 shares in the last quarter. Ingalls & Snyder LLC bought a new position in shares of Eupraxia Pharmaceuticals during the 2nd quarter worth $214,000. JPMorgan Chase & Co. increased its stake in shares of Eupraxia Pharmaceuticals by 593.2% during the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after buying an additional 16,017 shares during the period. Quadrature Capital Ltd purchased a new stake in Eupraxia Pharmaceuticals in the second quarter worth about $61,000. Finally, Bank of America Corp DE grew its holdings in Eupraxia Pharmaceuticals by 402.4% during the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after acquiring an additional 10,059 shares in the last quarter.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.